Comparative Pharmacology
Head-to-head clinical analysis: EYSUVIS versus FML.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EYSUVIS versus FML.
EYSUVIS vs FML
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Eysuvis (loteprednol etabonate ophthalmic suspension) is a corticosteroid that works by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid and subsequent synthesis of prostaglandins and leukotrienes, thereby reducing inflammation.
Agonist at glucocorticoid receptors, leading to inhibition of phospholipase A2 via annexin-1 induction, reducing prostaglandin and leukotriene synthesis; also suppresses cytokine production and inflammatory cell migration.
1 drop in each eye twice daily (approximately 12 hours apart) for 4 weeks.
Fluorometholone ophthalmic suspension 0.1%: Instill 1 drop into conjunctival sac 2-4 times daily. In severe conditions, may increase to 1 drop every hour initially.
None Documented
None Documented
Approximately 2-4 hours for loteprednol etabonate; clinical effect correlates with dosing interval (e.g., 4 times daily).
The terminal elimination half-life of fluorometholone is approximately 1.5 hours in plasma. Clinically, this short half-life allows for multiple daily dosing; however, ocular administration results in sustained local effects due to corneal binding.
Primarily renal (90-95% as unchanged drug and metabolites); minor biliary/fecal (<5%).
FML (fluorometholone) is primarily metabolized in the liver, with metabolites excreted renally. Approximately 70-80% of the dose is eliminated in urine as metabolites, with less than 5% as unchanged drug. Fecal excretion accounts for about 10%.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid